Care of heart failure (HF) patients results in a high burden on healthcare resources, and estimating prognosis is becoming increasingly important to triage resources wisely. Natriuretic peptides are recommended prognosticators in chronic HF. Our objective was to evaluate whether a multisensor HF index and alert algorithm (HeartLogic) replaces or augments current HF risk stratification.
D
espite significant advances in medical and device therapy during the past 30 years, the morbidity, mortality, and economic burden of heart failure (HF) remains high. 1, 2 However, because of the variability in patient outcome, estimating prognosis can be particularly challenging, and yet this is becoming increasingly important to allow limited healthcare resources to be prioritized wisely.
Traditionally, signs and symptoms have been the hallmark of clinical assessment of HF patients. Some of them, such as the third heart sound (S3) and jugular venous distension, have been known to be prognostic 3 but are subjective and challenged by difficulty in procurement through physical examination. 4, 5 The subsequent use of left ventricular ejection fraction and peak oxygen consumption to risk stratify patients has been largely superseded by an ever-increasing array of biomarkers, although the BNP (B-type natriuretic peptide/NT-proBNP [N-terminal pro-BNP]) remains the current benchmark. Recently, multivariate models have been developed using large clinical trial data, requiring numerous clinical variables many of which are dependent on an invasive blood sample and offer only a snapshot of risk at that given time. 6, 7 Moreover, these were developed for prognosticating mortality, and their utility for assessing risk of future HF events or establishing disease severity is not well understood. 8 Implantable cardiac devices have the potential to continuously monitor numerous physiological parameters via a variety of sensors. We recently reported on the development and validation of an implanted multisensor HF index and alert algorithm (HeartLogic) that predicted impending worsening HF events with 70% sensitivity and a median 34-day advance warning before an HF event at the nominal threshold configuration. 9 In this analysis, our objective was to assess the risk of HF events in patients and determine if a limited subset of patient follow-up with a meaningfully higher risk could be detected during the course of a year.
METHODS
The MultiSENSE study (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) has been previously published. 9 The analysis presented here is a post hoc evaluation using results from the MultiSENSE study and the HeartLogic index. In brief, MultiSENSE is an international, multicenter, nonrandomized study designed to develop and evaluate a multisensor based algorithm for the early detection of worsening HF. To be enrolled, patients were required to be implanted with an existing cardiac resynchronization therapy defibrillator (CRT-D; COGNIS; Boston Scientific, Marlborough, MA). During the baseline visit after enrollment, patient demographic and clinical status was collected, including NT-proBNP, and the patient's CRT-D had custom research firmware installed converting it to a Sensor Research Device that collected high-fidelity sensor data, including heart sounds, respiration, thoracic impedance, heart rate, and activity. Patients were followed for up to 12 months, at the end of which their device was reconverted to the market approved firmware.
Study data were collected and analyzed by the study sponsor. The authors had access to summarized patient data and could query any aspect of the data; P.H. Thakur, Q. An, S. Wehrenberg, and Y. Zhang had full access to the data and take responsibility for data and analysis integrity. Because of the proprietary nature of the sensor analysis and multiparameter algorithm, the data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Institutional review board approval was obtained at each center, and all patients provided written informed consent. The study was conducted in accordance with the ethical standards of the institutional and national research committees and with the 1964 Declaration of Helsinki and its later amendments.
HeartLogic HF Index and Alert Algorithm
HeartLogic is a proprietary algorithm using data obtained from a diverse set of implanted sensors embedded within a commercially available CRT-D chosen to target different aspects of HF pathophysiology associated with common signs and symptoms of HF. Several sensor trends were extracted, including first and third heart sounds, respiration rate, rapid shallow breathing index (the ratio of respiration rate to tidal volume), thoracic impedance, heart rate, and patient activity. Sensor changes from the patient's own baseline were aggregated and weighted on the basis of an individual daily risk to calculate the daily HeartLogic HF index. The HeartLogic index is designed to be updated daily and to issue an alert when the index crosses a user-configurable threshold. The alert is resolved once the HeartLogic index drops below the recovery threshold (see example in Figure 1 ).
Clinicians were blinded to the unique sensor data that included heart sounds, rapid shallow breathing index, and
WHAT IS NEW?
• An implantable cardiac device-based multisensor index and alert algorithm is able to identify periods of 10-fold increased risk of worsening heart failure events.
• The alert, when used in conjunction with a baseline measure of NT-proBNP (N-terminal pro-B-type natriuretic peptide), identified periods with a 50-fold increased risk of heart failure events during the majority of low-risk periods.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Healthcare resources can be focused on patients at elevated risk of heart failure events after a device alert, whereas low-risk patients can be reassured as they continue to be monitored with daily multisensor measurements of clinical signs of heart failure.
thoracic impedance, as well as the HeartLogic index and alert status throughout the study.
HF Events
An independent clinical events committee reviewed allcause death, hospitalizations, and outpatient visits with intravenous treatment or oral HF medications and adjudicated these as HF events if the patients had signs/symptoms of congestive HF and received augmented HF therapy while admitted or received unscheduled intravenous decongestive therapy as an outpatient. 10 Some of these HF events were unavailable for evaluating HeartLogic because they either occurred early after the device conversion before a sensor baseline could be established or occurred with missing sensor data due primarily to noncompliance with study follow-up schedule. Such HF events were screened out of the HeartLogic analysis data set based on predefined sensor data availability rules 9 but remained in the NT-proBNP analysis data set. The Clinical Events Committee was blinded to all device data and HeartLogic index and alerts within the study.
Event Rate Ratios
HeartLogic index values relative to a configurable threshold identified periods as IN an alert state versus OUT of an alert state. HF event rates were calculated separately during alert IN and OUT states by taking the ratio of the total count of usable HF events occurring in each state to the respective patient follow-up durations and expressed as events per patient-year (pt-yr; Figure 1 ). An event rate ratio was calculated as the ratio of event rates during IN versus OUT states. Event rates and ratios were calculated over all configurable HeartLogic thresholds ranging from 10 to 40, including the nominal threshold of 16.
For a clinical perspective, a similar calculation was performed with baseline NT-proBNP using a threshold of 1000 pg/mL. Event rate for NT-proBNP HIGH state was calculated as the ratio of total count of HF events in patients with concentrations equal to or over the defined threshold to the total follow-up duration in these patients ( Figure I in the Data Supplement). The calculation was repeated for concentration thresholds ranging from 500 to 1500 pg/mL.
Events rates were also calculated during HeartLogic IN and OUT states separately for patients with baseline NT-proBNP measurements above and below a range of concentrations (500 to 1500 pg/mL). Event rate ratios were obtained relative to the lowest risk group (HeartLogic OUT and NT-proBNP below threshold).
Statistical Analysis
Event rates and event rate ratios are calculated and graphically displayed using arithmetic values. Statistical comparisons of event rate ratios, 95% confidence interval (CI) and P values were derived from generalized estimating equations based on a negative binomial distribution and using an exchangeable correlation structure. The generalized estimating equations modeled events per pt-yr on explanatory factors while accounting for repeated assessment of event rates per patient, as a patient could contribute to the model both in the IN and OUT states, as well as for both the HeartLogic and NT-proBNP prognosticators. Modeled event rate ratios for NT-proBNP, and their associated 95% CIs, are derived from a generalized linear model with a negative binomial link function.
The independence of HeartLogic to baseline clinical variables was analyzed in a multivariable analysis. Univariate predictors to event rate ratios were analyzed, including age, sex, body mass index, resting heart rate, history of atrial fibrillation (AF) or atrial flutter, history of renal disease, history of diabetes mellitus, prior myocardial infarction, New York Heart Association class, left ventricular ejection fraction, systolic blood pressure, diastolic blood pressure, hematocrit, total hemoglobin, NT-proBNP, total plasma protein, potassium, sodium, creatinine, and blood urea nitrogen. Analysis of continuous variables was performed using clinically relevant cut points (Data Supplement). Variables with significant association to HF events were identified at a P value cutoff of 0.1 and were included in the multivariable model. All statistics were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC). 
RESULTS

Data Set Characterization
Nine hundred and seventy-four patients were enrolled at 93 centers (75 North America/13 Europe/5 Asia) between July 2010 and October 2013 of which 900 patients underwent device conversion, median patient follow-up was 393 days (25th/75th percentile, 387-399). Baseline characteristics of the patients are summarized in Table 1 . The data from the Development Set and Test Set were pooled together for this analysis (see the Data Supplement for the justification).
A total of 106 patients experienced 192 HF events, of which 23 were excluded because they happened within 45 days of initiation of sensor data collection (and thus did not have sufficient baseline to initialize HeartLogic), and 24 were excluded because of missing sensor data just before or at the time of the event. The overall prevalence of missing sensor data was low and only 5.1% of the days across the entire data set resulted in HeartLogic not being computed because of missing sensor data beyond the first 45 days of the start of sensor data collection. The remaining 145 (76%) events from 88 patients were usable for HeartLogic risk evaluation. The average event rate within the study was 0.20 events/pt-yr. Patients experienced an average of 2.07 state transitions (from OUT of alert to IN alert or vice versa) over follow-up per patient. A total of 487 (54%) patients experienced at least 1 HeartLogic state transition, 456 (51%) experienced at least 2 transitions, and 283 (31%) experienced at least 3 transitions. The average IN alert period was 37.8 days (median 30 days), and the average OUT of alert period (including patients who never had an alert) was 145.2 days (median 88 days).
HF Event Detection
The detection of HF events in the development set (n=500 patients) and sequestered test set (n=400 patients) has been previously described. 9 In brief, pertinent to this analysis the HeartLogic index was able to detect 70% of impending HF events with a median 34 days warning when using the nominal threshold of 16. The sensitivity ranged from a low of 22% at the highest configurable threshold (40) to a high of 80% at the lowest configurable threshold (10).
Event Rate Ratios
Of the total 727 patient-years follow-up with a valid HeartLogic index, 17% (120 pt-yr) were associated with IN HeartLogic alert state at the nominal threshold of 16. The proportion ranged from 4% to 27% across the range of configurable thresholds (Figure 2) .
At the nominal threshold of 16, IN HeartLogic alert state was associated with an event rate of 0.80 events/ pt-yr, whereas the OUT of alert state was associated with an event rate of 0.08 events/pt-yr, resulting in an event rate ratio of 10.6. The statistical model yielded an event rate ratio of 7.05 (CI, 4.69-10.61; P<0.0001). Event rates associated with the IN alert state progres- sively increased with the increasing configurable threshold until the highest thresholds where the sample size becomes sparse in the IN alert data set ( Figure 3A) . Event rates associated with the OUT of alert state progressively decreased with decreasing threshold indicating that lower HeartLogic thresholds progressively identified pools of patient population at reduced HF event risk. The event rate ratio was significantly >1.0 (P<0.0001) and consistently in the 8 to 12 range for the entire range of configurable thresholds ( Figure 3B ). An additional analysis was performed using a broader definition of adjudicated HF events, including patients admitted with a secondary cause of HF and nonhospitalization events with signs and symptoms of worsening HF and significant alterations to oral therapy for HF management, with similar results (Table I in the Data Supplement). Univariate analysis of the clinical factors (Table II in the Data Supplement) found the following to have a significance of P<0.10: history of AF or atrial flutter, history of renal disease, creatinine, NT-proBNP, New York Heart Association class, blood urea nitrogen, total plasma protein, resting heart rate, total hemoglobin, systolic blood pressure, history of diabetes mellitus, and left ventricular ejection fraction. These variables, along with HeartLogic with a threshold of 16, were included in a multivariable model ( Table 2 ). The event rate ratio for HeartLogic remained significant (4.78; CI, 2.94-7.75; P<0.0001) and greater than the event rate ratios for the other variables, indicating that HeartLogic remains an additional significant prognostication after adjustment for baseline clinical assessment variables. When performing the same multivariable analysis across the range of HeartLogic thresholds between 10 and 40, the adjusted event rate ratios ranged between 3.19 and 5.93.
We further analyzed the HeartLogic event rate ratio (using the nominal threshold of 16) separately across subgroups of patients evaluating the effect of demographics and comorbidities on HF event risk stratification (Figure 4) . HeartLogic continued to identify periods of elevated risk across all subgroups; without significant interaction among the subgroups with the exception of NT-proBNP and a history of ischemia or atrial arrhythmias.
A baseline NT-proBNP above a threshold of 1000 pg/ mL was associated with an event rate of 0.42 events/ pt-yr, whereas below the threshold was associated with an event rate of 0.07 events/pt-yr, resulting in an event rate ratio of 6.0 ( Figure IIA and IIB in the Data Supplement). The statistically modeled event rate ratio was 6.60 (CI, 3.95-11.04; P<0.0001). The relatively weaker performance of baseline NT-proBNP as compared to HeartLogic is expected as the single snapshot evaluation at baseline loses its relevance over time. Normal hemoglobin=13-16 g/dL (male) or 12-15 g/dL (female). Calculated using generalized estimating equations based on a negative binomial distribution. AF indicates atrial fibrillation; AFl, atrial flutter; BP, blood pressure; BUN, blood urea nitrogen; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association.
As the analysis window is shortened, a progressively improved prognostication is observed in contrast to the consistent stratification provided by the HeartLogic index (Table III in the Data Supplement). Event rates were also calculated in 4 distinct risk pools: HeartLogic IN versus OUT and baseline NT-proBNP HIGH versus LOW (Table IV in the Data Supplement). Figure 5 summarizes the stratification of HeartLogic at the nominal threshold of 16 and NT-proBNP at the threshold of 1000 pg/mL individually and combined. Patients with LOW baseline NT-proBNP and OUT of HeartLogic alert comprised the largest proportion of follow-up duration (53%) and had the lowest event rates (0.02 events/ pt-yr). In patients with a high-risk NT-proBNP, but remaining in an OUT of HeartLogic alert state (30% of follow-up), the event rate is 8× higher but still modest at 0.16 events/pt-yr. Risk was much higher in patients IN HeartLogic alert: those with LOW NT-proBNP had a 23.5× increased risk of an HF event (7% of follow-up; event rate, 0.47 events/pt-yr), and those with a HIGH NT-proBNP had a 50-fold increased risk of HF events (10% follow-up, 1.00 events/pt-yr) relative to the lowrisk group.
DISCUSSION
This study demonstrated that HeartLogic provides a measure of the risk of an HF event independent of baseline clinical variables, and the HF event rate was 10× higher when HeartLogic was IN alert state compared with OUT of an alert state. Furthermore, HeartLogic significantly augments the prognosis of a single snapshot NT-proBNP assessment at baseline for longer durations. Patients with HIGH baseline NT-proBNP when IN HeartLogic alert had a 50-fold higher event rate as compared to when patients with LOW baseline NT-proBNP when OUT of an alert state. The diagnostic sensors, while studied in CRT-D, could be integrated into other devices, such as implantable cardioverter defibrillators and pacemakers. It is exciting to propose that this dynamic algorithm could ultimately lead to appropriate clinical interventions and improved outcome for patients with HF.
The predictive performance of the HeartLogic index benefits from the daily measurements from multiple sensors which evaluate the various signs of HF decompensation. Device-based heart sounds sensor evaluates the S3; an audible S3 being a highly specific marker for patients with elevated left ventricular filling pressures 11 and device measured S3 being moderately sensitive and highly specific for detecting elevated left atrial pressures in preclinical experiments. 12 Furthermore, the first heart sound (S1) has been shown to diminish with reduced cardiac contractility. 12 The respiration sensors in the device detect elevated respiration rates 13 and labored breathing, as patients admitted for acute HF decompensation commonly present with dyspnea.
14 Thoracic impedance sensors are correlated with elevated pulmonary capillary wedge pressures 15 to detect pulmonary edema that occurs in the majority of patients hospitalized for HF. 16 Patient heart rate, measured using the intracardiac lead, and decreased patient activity, measured using the accelerometer within the pulse generator, may reflect decompensation in the HF patient. 17 Automatic daily evaluation of these sensor measurements is compared with the patient's own baseline, providing individualized detection of deterioration of the patient's status. Device interrogation will allow the clinician to review up to 12 months of daily HeartLogic indices and daily sensor trends in addition to atrial arrhythmia burden and an abbreviated history of tachyarrhythmia therapy ( Figure III in the Data Supplement) through the LATITUDE remote monitoring system. On a HeartLogic alert, clinicians will be informed of the degree of worsening in the S3, S3/ S1 ratio, thoracic impedance, respiratory rate, and night heart rate trends from their respective baseline.
The current gold standard markers of an adverse outcome in patients with HF are the BNP (or NT-proBNP), 18 which have been established as class IA recommendation for HF prognosis per American College of Cardiology Foundation/American Heart Association guidelines. 8 HF interventions, such as medical 19, 20 and device 21 therapies are associated with a reduction in these peptides (reflecting an improved prognosis), and so it is clear that the benefit of a single snapshot NT-proBNP becomes less relevant with time. There are examples of the utility of longitudinal NT-proBNP sampling, but as this is an invasive test, it is impractical to check this on a frequent basis. This points to a major advantage of HeartLogic which automatically reassesses risk daily and can significantly augment the prognosis of a single snapshot NTproBNP for up to a year, without the need for repeated blood draws or any additional patient effort, assuming patients have remote monitoring in place.
Device-based diagnostics are the focus of increasing attention. Remote monitoring of implantable defibrillators with a multiparameter alert (IN-TIME [Implant-Based Multiparameter Telemonitoring of Patients With Heart Failure] 22 ) for ventricular arrhythmias or shocks, atrial arrhythmias, patient activity, as well as other diagnostics, including malfunctions in the implantable system was found to improve patient survival, but reductions in HF admissions and New York Heart Association functional class worsening were nonsignificant. However, in the DOT-HF study (Diagnostic Outcome Trial in Heart Failure) 23 implantable cardioverter defibrillators and CRT-Ds which could alert patients to changes in intrathoracic impedance (OptiVol) saw a 79% increase in HF hospitalizations, as well as a tripling of outpatient visits, in those who were randomized to have an audible patient alert. In a more recent study (PARTNERS-HF [Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure Study] 24 ), daily HF scores were estimated by combining changes in intrathoracic impedance, AF burden (including rapid rates during AF), % CRT pacing, ventricular arrhythmias, night heart rate, heart rate variability, and patient activity. Although Cowie et al 25 found a 10-fold increase in risk between high-risk and low-risk groups, this study also had a sizable third medium group accounting for >40% of the population whose risk was intermediate. When we performed a similar 3-tier analysis using HeartLogic with the high-risk group defined as HeartLogic IN alert and the OUT of alert group divided into an intermediate risk (HeartLogic index ≥2) and low-risk (HeartLogic index <2; event rate, 0.05/ pt-yr; 41% of total patient follow-up) the event rate ratio between the high-and low-risk groups ranged from 11 to 29. At the threshold of 22, matching the 10% prevalence in the high-risk group of the Cowie et al 25 study, the event rate was 1.11 events/pt-yr with an event rate ratio of 22.2 ( Figure IV in the Data Supplement). However, in the clinical setting, binary logic based on HeartLogic Alert status will be more easily interpreted.
In our study, HeartLogic identified patients at higher risk of an HF event independent of all baseline clinical measures, including NT-proBNP. In addition, it significantly enhances the risk stratification offered by a single snapshot NT-proBNP during the following year. As previously reported, 9 the HeartLogic threshold of 16 was exceeded a median of 34 days before the event, and 89% of alerts occurred at least 2 weeks before the event. With an event rate ratio of 10 at the same HeartLogic threshold, this information could facilitate improved patient monitoring to focus care on patients in an active HeartLogic alert state. The risk of an HF event was exceptionally low (0.02 events/pt-yr) in the patients with LOW baseline NT-proBNP and OUT of HeartLogic alert, allowing patients to be somewhat reassured and healthcare resources to be prioritized elsewhere until a HeartLogic alert occurs. In contrast, the 50-fold increased risk of worsening HF in those with HIGH baseline NT-proBNP and IN HeartLogic alert should prompt healthcare resources to be focused on these patients to mitigate any potential HF deterioration. Thus, dynamic assessment using HeartLogic alerts either by itself or in conjunction with intermittent/ sparse NT-proBNP can automatically identify periods of time in which patients are at significantly increased risk of worsening HF with the potential to better triage resources to this vulnerable patient population.
The ability for HeartLogic to integrate into a clinical workflow, including alerting healthcare professionals at a point when patients may be presymptomatic, and the impact on patient outcomes and healthcare resources is currently unknown. Based on the ability of this index to discriminate high-and low-risk intervals, a study designed to optimize the clinical integration of HeartLogic and evaluate its impact on clinical outcomes is currently underway: the Multiple Cardiac Sensors for Management of Heart Failure (MANAGE-HF; URL: https://www.clinicaltrials.gov. Unique identifier: NCT03237858) clinical trial.
Limitations
This post hoc analysis was performed by pooling data from the development and test set cohorts of the Multi SENSE study. Although physicians were blinded to the HeartLogic index and the unique sensor data, they were not blinded to NT-proBNP results, which may have resulted in treatment modification, thereby limiting its predictive accuracy. Finally, negative binomial convergence was imperfect because of adjustment for multiple observations and the number of end points within the data set.
Patients may have received treatment through standard of care that could have aborted an HF event as defined by the study thus leading to lower calculated HF event rates.
Approximately 25% of HF events were censored because of sensor data unavailability in the MultiSENSE study. Half of the censored events were because of the event occurring during the initial 45-day window while the patient baseline was being developed, this is expected to proportionately decrease in the commercial implementation as patient follow-up will extend for a projected 10-year device longevity (with remote monitoring and HeartLogic turned on). The other half of censored events were because of memory overflow issues after missed follow-ups as the Sensor Research Device could only store up to 8 weeks of high-fidelity data, this should be solved in the commercial implementation as the volume of data logged is greatly reduced allowing storage of 12 months of the sensor measurements.
The risk of events was compared via event rate ratios rather than time-to-event methods (ie, hazard ratios) because of the large difference in time at risk for the IN alert and OUT of alert HeartLogic states. The majority (83%) of patient-days of follow-up were spent in the OUT state. Therefore, the distinct periods of risk in the IN state tend to be much shorter than those in the OUT state. The typical nonparametric time-to-event methods only utilize the times at which patients in both the IN and OUT states are at risk, thereby losing information from later times when only patients in the OUT state are at risk. Therefore, events and follow-up times were summed across distinct IN and OUT states, with event rates calculated as the rate of HF events per pt-yr of follow-up and event rates compared via rate ratios.
The results are based on a retrospective analysis of the MultiSENSE study which validated the HeartLogic algorithm in HF patients with reduced ejection fraction and New York Heart Association class II, III, or IV. Further evaluation is necessary to determine the generalizability to this the broader population of HF patients. The algorithm performance has not been evaluated in HF patients with preserved ejection fraction.
Conclusions
Dynamic assessment using HeartLogic can automatically identify time-intervals when cardiac resynchronization therapy indicated patients are at significantly increased risk of worsening HF. Furthermore, HeartLogic alerts significantly augment the ability of baseline NT-proBNP to identify periods with an elevated risk of HF event for up to a year. Thus, HeartLogic assessment by itself or in conjunction with intermittent/sparse NT-proBNP could help better triage resources in a timely manner to this vulnerable patient population. A further study to prospectively assess whether a clinical intervention in device indicated patients based on a HeartLogic alert improves patient outcome is underway.
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